Powered by

Astra spins off six of its early stage drugs

Mar 01, 2018 - The Daily Telegraph (London)

ASTRAZENECA is spinning off six early-stage experimental drugs into a new $250m (£181m) stand-alone biotech arm focused on severe autoimmune diseases. The spin-off of the three clinical and three pre-clinical biological compounds, announced yesterday, is the latest example of the drug maker pruning its non-core drug development work to focus on priority areas, notably in cancer.

Chief executive Pascal Soriot said earlier this month that AstraZeneca had a drug pipeline that was "over-sized...